Payment overview · 2025
General Payments
$766.27
52 reported records · 12 companies
Healthcare provider profile · identity verified
Jaime Oakley, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENEVILLE, TN · NPI 1013966886
Verified facts
What the public records show
CMS Open Payments records show Jaime Oakley, MD received $766.27 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $191.50 | 25.0% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.00 | 18.3% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $87.32 | 11.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.02 | 9.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.67 | 8.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.79 | 6.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.57 | 6.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.88 | 4.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.66 | 3.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.05 | 3.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.72 | 2.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.09 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $766.27 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $140.33 | 16 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $87.32 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $80.87 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.02 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $65.67 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.13 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.13 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.17 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $30.88 | 1 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.55 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 140 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 589 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 358 | 51 |
| Omeprazole | Omeprazole | 321 | 83 |
| Gabapentin | Gabapentin | 317 | 64 |
| Lisinopril | Lisinopril | 315 | 85 |
| Alprazolam | Alprazolam | 260 | 45 |
| Meloxicam | Meloxicam | 238 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 66 |
| Metformin Hcl | Metformin Hcl | 228 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 210 | 67 |
| Simvastatin | Simvastatin | 199 | 47 |
| Losartan Potassium | Losartan Potassium | 198 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 53 |
| Famotidine | Famotidine | 175 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 23 |
| Furosemide | Furosemide | 157 | 48 |
| Lovastatin | Lovastatin | 157 | 41 |
| Eliquis | Apixaban | 140 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 41 |
| Benazepril Hcl | Benazepril Hcl | 123 | 33 |
| Metformin Hcl Er | Metformin Hcl | 116 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 111 | 14 |
| Allopurinol | Allopurinol | 107 | 31 |
| Carvedilol | Carvedilol | 107 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 36 |
| Montelukast Sodium | Montelukast Sodium | 103 | 23 |
| Potassium Chloride | Potassium Chloride | 101 | 29 |
| Atenolol | Atenolol | 96 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 28 |
| Warfarin Sodium | Warfarin Sodium | 93 | 18 |
| Glimepiride | Glimepiride | 91 | 25 |
| Sertraline Hcl | Sertraline Hcl | 90 | 24 |
| Jardiance | Empagliflozin | 89 | 22 |
| Diazepam | Diazepam | 86 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 22 |
| Alendronate Sodium | Alendronate Sodium | 75 | 22 |
| Clonazepam | Clonazepam | 74 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 21 |
| Prednisone | Prednisone | 64 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 20 |
| Ozempic | Semaglutide | 63 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 16 |
| Donepezil Hcl | Donepezil Hcl | 56 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 15 |
| Spironolactone | Spironolactone | 55 | 15 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Finasteride | Finasteride | 52 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 11 |
| Estradiol | Estradiol | 47 | 14 |
| Tramadol Hcl | Tramadol Hcl | 46 | 14 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | 13 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 17 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 16 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 24 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Felodipine Er | Felodipine | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 15 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Glipizide | Glipizide | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $766.27 · 52 records | ABBVIE INC. | ABRYSVO, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, Fluad, Flucelvax, General - Erectile Dysfunction, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error